Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
VIR Stock Forecast 2025-2026
$5.13
Current Price
$712.64M
Market Cap
Buy 10
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to VIR Price Targets
+504.3%
To High Target of $31.00
+192.4%
To Median Target of $15.00
+133.9%
To Low Target of $12.00
VIR Price Momentum
-13.9%
1 Week Change
-15.1%
1 Month Change
-46.6%
1 Year Change
-30.1%
Year-to-Date Change
-64.5%
From 52W High of $14.45
+23.5%
From 52W Low of $4.16
📊 TOP ANALYST CALLS
Did VIR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Vir Biotechnology is one of their latest high-conviction picks.
Latest VIR Stock Price Targets & Analyst Predictions
Based on our analysis of 17 Wall Street analysts, VIR has a bullish consensus with a median price target of $15.00 (ranging from $12.00 to $31.00). The overall analyst rating is N/A (N/A/10). Currently trading at $5.13, the median forecast implies a 192.4% upside. This outlook is supported by 10 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Gena Wang at Barclays, projecting a 504.3% upside. Conversely, the most conservative target is provided by Cory Kasimov at Evercore ISI Group, suggesting a 133.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
VIR Analyst Ratings
10
Buy
0
Hold
0
Sell
VIR Price Target Range
Low
$12.00
Average
$15.00
High
$31.00
Current: $5.13
Latest VIR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for VIR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Sep 15, 2025 | HC Wainwright & Co. | Patrick R. Trucchio | Buy | Reiterates | $15.00 |
| Sep 3, 2025 | Evercore ISI Group | Cory Kasimov | Outperform | Initiates | $12.00 |
| Aug 27, 2025 | B of A Securities | Geoff Meacham | Buy | Upgrade | $14.00 |
| Jul 11, 2025 | Raymond James | Sean McCutcheon | Outperform | Initiates | $12.00 |
| May 22, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $14.00 |
| May 12, 2025 | Needham | Joseph Stringer | Buy | Maintains | $14.00 |
| Apr 17, 2025 | Goldman Sachs | Paul Choi | Buy | Maintains | $21.00 |
| Feb 28, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $110.00 |
| Feb 28, 2025 | Barclays | Gena Wang | Overweight | Maintains | $31.00 |
| Feb 27, 2025 | Needham | Joseph Stringer | Buy | Reiterates | $19.00 |
| Jan 31, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $110.00 |
| Jan 13, 2025 | Leerink Partners | Roanna Ruiz | Outperform | Maintains | $20.00 |
| Jan 10, 2025 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $110.00 |
| Jan 9, 2025 | Morgan Stanley | Michelle Gilson | Overweight | Upgrade | $20.00 |
| Jan 9, 2025 | JP Morgan | Eric Joseph | Neutral | Maintains | $14.00 |
| Nov 20, 2024 | Needham | Joseph Stringer | Buy | Reiterates | $19.00 |
| Nov 20, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $110.00 |
| Nov 4, 2024 | HC Wainwright & Co. | Patrick Trucchio | Buy | Reiterates | $110.00 |
| Nov 4, 2024 | Barclays | Gena Wang | Overweight | Maintains | $26.00 |
| Nov 1, 2024 | Needham | Joseph Stringer | Buy | Reiterates | $19.00 |
Vir Biotechnology Inc. (VIR) Competitors
The following stocks are similar to Vir Biotechnology based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Vir Biotechnology Inc. (VIR) Financial Data
Vir Biotechnology Inc. has a market capitalization of $712.64M with a P/E ratio of -1.3x. The company generates $19.00M in trailing twelve-month revenue with a 98.7% profit margin.
Revenue growth is -60.5% quarter-over-quarter, while maintaining an operating margin of -9,768.5% and return on equity of -46.2%.
Valuation Metrics
Market Cap
$712.64M
Enterprise Value
$274.14M
P/E Ratio
-1.3x
PEG Ratio
0.1x
Price/Sales
37.4x
Growth & Margins
Revenue Growth (YoY)
-60.5%
Gross Margin
+98.9%
Operating Margin
-9,768.5%
Net Margin
+98.7%
EPS Growth
+9.6%
Financial Health
Cash/Price Ratio
+85.0%
Current Ratio
7.0x
Debt/Equity
10.8x
ROE
-46.2%
ROA
-24.7%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Vir Biotechnology Inc. (VIR) Business Model
About Vir Biotechnology Inc.
What They Do
Develops innovative treatments for infectious diseases.
Business Model
The company focuses on creating therapies and preventative solutions by leveraging immune system mechanisms. It generates revenue through the development and commercialization of its products, often collaborating with other organizations to enhance its research and development capabilities.
Additional Information
Vir Biotechnology is committed to addressing global health challenges, particularly in the context of emerging infectious diseases. Its emphasis on scientific innovation positions it as a key player in public health and pandemic preparedness, making it an attractive investment in a rapidly evolving sector.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
408
CEO
Dr. Marianne De Backer M.B.A., M.Sc., Ph.D.
Country
United States
IPO Year
2019
Website
www.vir.bioVir Biotechnology Inc. (VIR) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Vir Biotechnology, Inc. (VIR) Reports Q3 Loss, Misses Revenue Estimates
Vir Biotechnology (VIR) delivered earnings and revenue surprises of -67.14% and -96.59%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Nov 05, 2025
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
Vir Biotechnology completed enrollment for ECLIPSE 1, a Phase 3 trial assessing the safety and efficacy of tobevibart and elebsiran for chronic hepatitis delta.
Why It Matters
Completion of enrollment in the ECLIPSE 1 trial positions Vir Biotechnology for potential regulatory approval, influencing market confidence and future revenue prospects in treating chronic hepatitis delta.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Vir Biotechnology, Inc. (Nasdaq: VIR) will report Q3 2025 financial results on November 5, 2025, and host a conference call at 1:30 p.m. PT. Details will be available on their Investor News page.
Why It Matters
Vir Biotechnology's upcoming financial results and corporate update could impact stock performance, providing insights into growth, profitability, and strategic direction, influencing investor sentiment.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Vir Biotechnology (VIR) shares rose sharply with above-average trading volume, but recent earnings estimate revisions may not lead to further price increases soon.
Why It Matters
Vir Biotechnology's share surge and higher trading volume indicate strong investor interest. However, the uncertainty in earnings estimates suggests potential price stabilization ahead.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Vir Biotechnology has initiated dosing for the first patient in Part 3 of its Phase 1 trial for VIR-5500, a T-cell engager targeting PSMA in metastatic castration-resistant prostate cancer.
Why It Matters
The dosing of the first patient in a Phase 1 trial for VIR-5500 signals progress in cancer treatment, potentially boosting Vir Biotechnology's stock if successful results are achieved.
Source: Business Wire
Market Sentiment:
Neutral
Quick Summary
Vir Biotechnology will present Week 48 results from its SOLSTICE Phase 2 study on tobevibart and elebsiran for chronic hepatitis delta at AASLD 2025, November 7-11 in Washington, D.C.
Why It Matters
The announcement of positive clinical study results from Vir Biotechnology could enhance investor confidence and drive stock performance, especially in the biotech sector focused on liver diseases.
Source: Business Wire
Market Sentiment:
Neutral
Vir Biotechnology, Inc. (VIR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
1 month ago
Quick Summary
Vir Biotechnology, Inc. (NASDAQ:VIR) will participate in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025, at 4:05 PM EDT.
Why It Matters
Vir Biotechnology's participation in a major healthcare conference highlights its strategic position and potential for investor interest, particularly regarding future developments and partnerships.
Source: Seeking Alpha
Market Sentiment:
Neutral
Frequently Asked Questions About VIR Stock
What is Vir Biotechnology Inc.'s (VIR) stock forecast for 2026?
Based on our analysis of 17 Wall Street analysts, Vir Biotechnology Inc. (VIR) has a median price target of $15.00. The highest price target is $31.00 and the lowest is $12.00.
Is VIR stock a good investment in 2026?
According to current analyst ratings, VIR has 10 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $5.13. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for VIR stock?
Wall Street analysts predict VIR stock could reach $15.00 in the next 12 months. This represents a 192.4% increase from the current price of $5.13. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Vir Biotechnology Inc.'s business model?
The company focuses on creating therapies and preventative solutions by leveraging immune system mechanisms. It generates revenue through the development and commercialization of its products, often collaborating with other organizations to enhance its research and development capabilities.
What is the highest forecasted price for VIR Vir Biotechnology Inc.?
The highest price target for VIR is $31.00 from Gena Wang at Barclays, which represents a 504.3% increase from the current price of $5.13.
What is the lowest forecasted price for VIR Vir Biotechnology Inc.?
The lowest price target for VIR is $12.00 from Cory Kasimov at Evercore ISI Group, which represents a 133.9% increase from the current price of $5.13.
What is the overall VIR consensus from analysts for Vir Biotechnology Inc.?
The overall analyst consensus for VIR is bullish. Out of 17 Wall Street analysts, 10 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $15.00.
How accurate are VIR stock price projections?
Stock price projections, including those for Vir Biotechnology Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 9, 2025 12:13 AM UTC